Shots:

• AstraZeneca (AZ) will receive $5M option license fee and additional $20M on approval of Duaklir (aclidinium / formoterol) (product of AZ) from Circassia. Circassia to get US commercialization rights for Tudorza (aclidinium)
• AZ has also filled sNDA for Tudorza to the US FDA on basis of ASCENT study results- with expected PDUFA date 31 Mar- 2019
• Tudorza (aclidinium) is a twice daily anticholinergic- indicated for COPD. Duaklir (aclidinium / formoterol) is a FD dry powder of muscarinic antagonist aclidinium bromide & beta agonist formoterol fumarate delivered by breath-actuated multi-dose inhaler Pressair

Ref: Circassia | Image: AstraZeneca